Healthcare Industry News: triple negative breast cancer
News Release - October 29, 2018
OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development OfficerSAN DIEGO and NEW JERSEY, Oct. 29, 2018 -- (Healthcare Sales & Marketing Network) -- OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced the appointment of Kellie Malloy Foerter to the position of Chief Clinical Development Officer.
As Chief Clinical Development Officer, Ms. Malloy Foerter will be responsible for leading OncoSec's ongoing registration-enabled KEYNOTE-695, a global, multicenter Phase 2b, open-label trial of intratumoral delivery of TAVOTM (tavokinogene telseplasmid / plasmid IL-12) with intravenous KEYTRUDA® (pembrolizumab) in patients with refractory, unresectable Stage III or Stage IV metastatic melanoma who have failed prior anti-PD-1 treatment with KEYTRUDA or OPDIVO® (nivolumab). In addition to working to rapidly advance OncoSec's growing clinical pipeline, she will also be responsible for leading OncoSec's second ongoing TAVOTM / KEYTRUDA® combination clinical trial in triple negative breast cancer (TNBC), KEYNOTE-890.
"I am delighted to welcome Kellie to the OncoSec team, as I know firsthand the rigor and creativity she brings with respect to clinical trial design, execution and analysis. I have no doubt she will an invaluable resource to the company as we continue to advance our clinical development pipeline, including both KEYNOTE-695 and KEYNOTE-890," said Daniel J. O'Connor, President and Chief Executive Officer of OncoSec.
With nearly three decades of experience in clinical research, Ms. Malloy Foerter joins OncoSec from Syneos Health, where she served as Executive Vice President and General Manager, Clinical Solutions. As a member of the Syneos Health Clinical executive leadership team, Ms. Malloy Foerter was responsible for the development and growth of multiple portfolios across therapeutic areas which included a strong focus on oncology and hematology trials, for the world's leading biopharmaceutical companies. Earlier, Ms. Malloy Foerter spent 20 years at inVentiv Health (previously PharmaNet) where she held multiple positions of increasing responsibility, most recently serving as Senior Vice President, Clinical Research. Prior to inVentiv, she served as Senior Project Associate, Clinical Research Associate and Clinical Studies Assistant at Covance.
In connection with her appointment, Ms. Malloy Foerter received a one-time inducement award of 200,000 stock options and 50,000 restricted stock units (RSUs), of which 50,000 options (25%) and 12,500 RSUs (25%) are fully vested as of the grant date. The remaining options and RSUs vest over a three-year period. The Company approved the award as an inducement material to Ms. Malloy Foerter entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. OPDIVO® is a registered trademark Bristol-Meyers Squibb.
About OncoSec Immunotherapies
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. OncoSec's lead immunotherapy platform – TAVOTM (tavokinogene telseplasmid) – enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVOTM as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders. Results from recently completed clinical studies of TAVOTM have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach. In addition to TAVOTM, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its ImmunoPulse® platform. For more information, please visit www.oncosec.com.
Source: OncoSec Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.